Monoclonal antibodies directed to IL-5 or its receptor (IL-5R) have been created, and these antibodies have been incorporated into asthma treatment guidelines, as in the case of mepolizumab anti-IL-5 monoclonal antibody, benralizumab anti-eosinophilic humanized and afucosylated monoclonal antibody (IgG1, kappa), and others where modifications have been carried out with proteomics (see Figure 1) [15]. The gene discussed is IL5; the disease is asthma.